Armed phages are heading for clinical trials

Armed phages are heading for clinical trials

Armed phages, engineered to carry a CRISPR–Cas , have demonstrated remarkable efficacy in combating Escherichia coli infections in animal models. Led by Antonia P. Sagona and Jessica Maree Lewis from the School of Life Sciences at the University of Warwick in Coventry, UK, this research represents significant progress in the fight against bacterial infections.

By harnessing the precision of CRISPR–Cas technology within the context of phage therapy, the study showcases a novel approach to combatting bacterial pathogens. Notably, the engineered phages exhibit the ability to mitigate E. coli infections without triggering adverse host immune responses, marking a critical advancement in therapeutic safety and efficacy.

The potential implications of this research extend far beyond the laboratory, offering hope for the development of innovative treatments for bacterial infections that are increasingly resistant to traditional antibiotics. With clinical trials, the prospect of armed phages as a viable therapeutic option is now within reach, promising a new era in infection management.

Article DOI.

Image Credits: By Freepik